查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1668014

特發性肺纖維化市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物類型、給藥途徑、配銷通路、地區和競爭細分，2020-2030 年預測

Idiopathic Pulmonary Fibrosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球特發性肺纖維化市場價值為 36.4 億美元，預計到 2030 年將達到 53.9 億美元，預測期內複合年成長率為 6.72%。特發性肺纖維化（IPF）這種肺部疾病很危險。當你吸氣時，氧氣會透過肺部的小氣囊進入血液。然後它會進入你的內部器官。 Prescriber 於 2022 年 7 月發布的流行病學資料顯示，歐洲特發性肺纖維化年發病率為每 10 萬人 0.22 至 7.4 例，僅在英國就報告了約 32,500 例。

市場概況
預測期 2026-2030
2024 年市場規模 36.4 億美元
2030 年市場規模 53.9 億美元
2025-2030 年複合年成長率 6.72％
成長最快的領域 吡非尼酮
最大的市場 北美洲

由於特發性肺纖維化 (IPF)，您的肺部會因疤痕組織而變得阻塞。隨著時間的推移，情況變得更糟。就像皮膚割傷後留下的疤痕一樣，IPF 疤痕組織很緻密。它會抑制氧氣從肺部向血液的輸送，可能導致身體無法正常運作。特發性肺纖維化可以存在很長時間而不會出現任何症狀。當人們接觸到污染、某些藥物或疾病等因素時，可能會罹患肺纖維化。然而，醫師並不確定 IPF 的病因。

IPF 的診斷需要結合病史、身體檢查、肺功能測試、高解析度電腦斷層掃描 (HRCT) 以及某些情況下的肺部活體組織切片。 IPF 通常很難診斷，因為其症狀可能與其他肺部疾病的症狀重疊。高解析度電腦斷層掃描 (HRCT) 和生物標記的識別等改進的診斷技術使得能夠更早、更準確地檢測出 IPF。這增加了尋求治療的患者數量。對特發性肺纖維化（IPF）新藥和新療法的持續研究和開發帶來了新療法的推出，擴大了患者的可用治療選擇。創新療法的批准是市場發展的驅動力。針對特發性肺纖維化 (IPF) 症狀和早期診斷重要性的宣傳活動和教育措施的不斷加強，促使更多患者尋求醫療治療。醫療保健專業人員也能夠更好地識別這種疾病。以患者為中心的照護（包括支持團體、患者權益以及改善 IPF 患者的生活品質）已成為市場促進因素。病患權益組織在提高意識和改善病患照護方面發揮著至關重要的作用。

主要市場促進因素

診斷方面的進展

主要市場挑戰

治療費用高昂

主要市場趨勢

遺傳和環境因素研究

分段洞察

配銷通路洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球特發性肺纖維化市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類型（吡非尼酮、尼達尼布等）
    • 依給藥途徑（腸胃外、口服、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：北美特發性肺纖維化市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第 7 章：歐洲特發性肺纖維化市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太特發性肺纖維化市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲特發性肺纖維化市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲特發性肺纖維化市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如果有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • Cipla Limited
  • Shionogi & Co., Ltd
  • Bristol-Myers Squibb Company
  • United Therapeutics Corporation
  • FibroGen, Inc
  • Pliant Therapeutics, Inc
  • Galecto, Inc.
  • CSL Behring

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 19233

lobal Idiopathic Pulmonary Fibrosis Market was valued at USD 3.64 Billion in 2024 and is expected to reach USD 5.39 Billion by 2030 with a CAGR of 6.72% during the forecast period. The lung condition idiopathic pulmonary fibrosis (IPF) is dangerous. When you breathe in, oxygen enters your bloodstream through small air sacs in your lungs. It then makes its way to your inside organs. Epidemiological data from Prescriber, published in July 2022, indicates that the annual incidence of idiopathic pulmonary fibrosis in Europe ranges from 0.22 to 7.4 cases per 100,000 individuals, with approximately 32,500 cases reported in the United Kingdom alone.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.64 Billion
Market Size 2030USD 5.39 Billion
CAGR 2025-20306.72%
Fastest Growing SegmentPirfenidone
Largest MarketNorth America

Your lungs get congested with scar tissue because of IPF. With time, it becomes worse. Like the scars you receive on your skin after a cut, the IPF scar tissue is dense. It inhibits the transfer of oxygen from your lungs to your blood, which might prevent your body from functioning properly. Idiopathic pulmonary fibrosis can exist for a very long time without any symptoms showing up. When someone is exposed to anything like pollution, certain medications, or an illness, they may develop pulmonary fibrosis. Doctors are unsure of what causes IPF, though.

Diagnosing IPF involves a combination of medical history, physical examination, lung function tests, high-resolution computed tomography (HRCT) scans, and, in some cases, a lung biopsy. IPF is often challenging to diagnose because its symptoms can overlap with those of other lung diseases. Improved diagnostic techniques, such as high-resolution computed tomography (HRCT) and the identification of biomarkers, have enabled earlier and more accurate detection of IPF. This has increased the number of patients seeking treatment. The ongoing research and development of new drugs and therapies for IPF have led to the introduction of novel treatments, which expand the available options for patients. The approval of innovative therapies is a driving force in the market. Increased awareness campaigns and educational initiatives about IPF symptoms and the importance of early diagnosis have resulted in more patients seeking medical care. Healthcare professionals are also better equipped to recognize the disease. The focus on patient-centered care, including support groups, patient advocacy, and improving the quality of life for IPF patients, has become a driving factor in the market. Patient advocacy organizations play a crucial role in raising awareness and improving patient care.

Key Market Drivers

Advancements in Diagnosis

High-Resolution Computed Tomography (HRCT) imaging has become a gold standard in diagnosing IPF. It provides detailed images of the lungs, allowing healthcare professionals to detect characteristic patterns of fibrosis. HRCT is non-invasive and has significantly improved the accuracy of IPF diagnosis. Ongoing research into biomarkers, such as specific proteins or genetic markers, has the potential to aid in early diagnosis and disease monitoring. Identifying biomarkers associated with IPF can help distinguish it from other lung conditions. Minimally invasive lung biopsy techniques, such as transbronchial cryobiopsy and endobronchial ultrasound-guided biopsy, offer alternatives to traditional surgical biopsies. These techniques provide tissue samples for analysis, aiding in the confirmation of IPF diagnosis.

Multi-Disciplinary Discussion (MDD) approach involves a team of specialists, including radiologists, pulmonologists, and pathologists, who jointly evaluate patient data, imaging, and biopsy results. This collaborative approach enhances the accuracy of IPF diagnosis. AI and machine learning algorithms have been applied to HRCT scans and other patient data to improve diagnostic accuracy. These technologies can assist in identifying patterns and characteristics of IPF that may be missed by human observers. Telemedicine has become a valuable tool, especially during the COVID-19 pandemic. It allows healthcare professionals to remotely assess patients, review diagnostic images, and provide consultation for individuals in remote or underserved areas. Genetic testing for specific gene mutations associated with familial IPF can help confirm the diagnosis in cases where a family history of the disease is present. International guidelines and consensus statements, such as those from the American Thoracic Society (ATS) and the European Respiratory Society (ERS), have provided standardized criteria for diagnosing IPF, facilitating consistency in diagnosis. Improved understanding of the clinical presentation and symptoms of IPF has enabled healthcare providers to diagnose the disease more accurately. Common symptoms include progressive breathlessness and dry cough. Bronchoalveolar Lavage (BAL) is a diagnostic procedure that involves collecting fluid from the air sacs in the lungs. It can help rule out other lung diseases and contribute to the diagnostic process. This factor will help in the development of the Global Idiopathic Pulmonary Fibrosis Market.

Key Market Challenges

High Cost of Treatment

Idiopathic Pulmonary Fibrosis (IPF) is a chronic and often progressive disease that requires long-term treatment. The high cost of medications, therapy, and healthcare services can impose a substantial financial burden on patients and their families, potentially leading to financial stress. Some IPF treatments, especially newer and more advanced therapies, may not be fully covered by health insurance plans. This can result in out-of-pocket expenses for patients, making it difficult for them to access necessary treatments. The high cost of IPF treatment can create disparities in access to care. Patients with limited financial resources may face barriers to accessing the most effective therapies, leading to disparities in outcomes. The cost of treatment can impact patients' adherence to prescribed medications and therapies. Patients may reduce or skip doses due to cost concerns, which can affect the effectiveness of the treatment. The high cost of IPF treatment places a financial burden on healthcare systems and insurance providers, potentially limiting the availability of certain treatments or leading to increased healthcare costs for society. High treatment costs can lead to financial toxicity, which has a negative impact on patients' overall well-being. This can include increased stress, anxiety, and reduced quality of life. Pharmaceutical companies face significant research and development costs when developing new IPF treatments. The high cost of development and regulatory approval can contribute to the high prices of these therapies once they reach the market. High costs can lead some patients to discontinue or delay their treatment, which may result in disease progression and more severe health outcomes.

Key Market Trends

Research into Genetic and Environmental Factors

Research into genetic factors helps identify individuals who may be at a higher risk of developing IPF. This knowledge can lead to personalized screening and preventative strategies. Genetic and environmental research may reveal biomarkers that can be used for early detection and diagnosis of IPF, enabling healthcare providers to intervene at an earlier, potentially more treatable stage of the disease. Identifying genetic and environmental risk factors allows for risk assessment and counseling for individuals with a family history of IPF or who have been exposed to certain environmental triggers.

Genetic research can help identify specific pathways and mechanisms underlying IPF. This knowledge may lead to the development of targeted therapies that address the root causes of the disease. Understanding the genetic and environmental factors contributing to an individual's IPF can inform the development of personalized treatment plans, optimizing therapy for each patient's unique needs. Research into environmental factors, such as exposure to certain toxins or pollutants, can help identify strategies for reducing exposure and preventing the development or exacerbation of IPF. Patients with IPF may benefit from genetic counseling to understand the hereditary aspects of the disease, particularly in cases of familial IPF. Insights gained from genetic and environmental research can uncover novel therapeutic targets, which may lead to the development of innovative treatments for IPF.

Segmental Insights

Distribution Channel Insights

In 2024, the Global Idiopathic Pulmonary Fibrosis Market largest share was held by hospital pharmacies segment in the forecast period and is predicted to continue expanding over the coming years. In some regions, a significant proportion of IPF patients receive treatment on an inpatient basis, particularly during acute exacerbations or advanced stages of the disease. Hospital pharmacies are responsible for dispensing and managing medications for these inpatients. Hospitals often play a key role in conducting clinical trials for new IPF treatments. The distribution and management of trial medications may involve hospital pharmacies. IPF treatment can involve complex medication regimens, including the use of oxygen therapy, immunosuppressive drugs, and other specialized medications. Hospital pharmacies are equipped to handle these complex regimens. Regional healthcare regulations and reimbursement policies can influence the distribution of medications. In some cases, regulations or policies may favour or require hospital-based distribution of certain medications.

Key Market Players

  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • Cipla Limited
  • Shionogi & Co., Ltd
  • Bristol-Myers Squibb Company
  • United Therapeutics Corporation
  • FibroGen, Inc
  • Pliant Therapeutics, Inc
  • Galecto, Inc.
  • CSL Behring

Report Scope:

In this report, the Global Idiopathic Pulmonary Fibrosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Idiopathic Pulmonary Fibrosis Market, By Drug Type:

  • Pirfenidone
  • Nintedanib
  • others
  • Idiopathic Pulmonary Fibrosis Market, By Route of Administration
  • Oral
  • Parenteral
  • Others

Idiopathic Pulmonary Fibrosis Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Idiopathic Pulmonary Fibrosis Market, By region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Idiopathic Pulmonary Fibrosis Market.

Available Customizations:

Global Idiopathic Pulmonary Fibrosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Idiopathic Pulmonary Fibrosis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Pirfenidone, Nintedanib, others)
    • 5.2.2. By Route of Administration (Parenteral, Oral, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Idiopathic Pulmonary Fibrosis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Idiopathic Pulmonary Fibrosis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. United Kingdom Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route Of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Italy Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route Of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. France Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route Of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route Of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route Of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route Of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route Of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route Of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Route Of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Route Of Administration
        • 8.3.5.2.3. By Distribution Channel

9. South America Idiopathic Pulmonary Fibrosis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route Of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route Of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Idiopathic Pulmonary Fibrosis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route Of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route Of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route Of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route Of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Boehringer Ingelheim International GmbH
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. F. Hoffmann-La Roche Ltd.
  • 14.3. Cipla Limited
  • 14.4. Shionogi & Co., Ltd
  • 14.5. Bristol-Myers Squibb Company
  • 14.6. United Therapeutics Corporation
  • 14.7. FibroGen, Inc
  • 14.8. Pliant Therapeutics, Inc
  • 14.9. Galecto, Inc.
  • 14.10. CSL Behring

15. Strategic Recommendations

16. About Us & Disclaimer